Fig. 1From: Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trialSafety. Serial potassium values from baseline through the end of the 36-month open label extension period are shown; black lines indicate younger subjects who were on placebo and gray lines were older subjects on eplerenone during the initial 12-month double blind RCT. One result in a subject initially on placebo was 5.7 mmol/L (*) at 13 months (1 month after starting open-label eplerenone); this was repeated and found to be 3.7 mmol/L. Potassium level in a hemolyzed sample at the 36 month visit was 5.3 mmol/L (**)Back to article page